- Home
- INO vs IVVD Comparison
INO vs IVVD Comparison
Compare INO & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- IVVD
- Stock Information
- Founded
- INO 1979
- IVVD 2020
- Country
- INO United States
- IVVD United States
- Employees
- INO N/A
- IVVD N/A
- Industry
- INO Medical/Dental Instruments
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- INO Health Care
- IVVD Health Care
- Exchange
- INO Nasdaq
- IVVD Nasdaq
- Market Cap
- INO 69.3M
- IVVD 63.4M
- IPO Year
- INO 1998
- IVVD 2021
- Fundamental
- Price
- INO $1.96
- IVVD $0.52
- Analyst Decision
- INO Buy
- IVVD Strong Buy
- Analyst Count
- INO 5
- IVVD 3
- Target Price
- INO $8.80
- IVVD $3.85
- AVG Volume (30 Days)
- INO 1.9M
- IVVD 1.2M
- Earning Date
- INO 08-12-2025
- IVVD 08-14-2025
- Dividend Yield
- INO N/A
- IVVD N/A
- EPS Growth
- INO N/A
- IVVD N/A
- EPS
- INO N/A
- IVVD N/A
- Revenue
- INO $182,337.00
- IVVD $46,210,000.00
- Revenue This Year
- INO N/A
- IVVD $345.16
- Revenue Next Year
- INO $20,588.06
- IVVD $161.08
- P/E Ratio
- INO N/A
- IVVD N/A
- Revenue Growth
- INO N/A
- IVVD 1941.08
- 52 Week Low
- INO $1.30
- IVVD $0.35
- 52 Week High
- INO $7.76
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- INO 66.94
- IVVD 32.49
- Support Level
- INO $1.80
- IVVD $0.48
- Resistance Level
- INO $2.08
- IVVD $0.65
- Average True Range (ATR)
- INO 0.12
- IVVD 0.06
- MACD
- INO 0.06
- IVVD -0.03
- Stochastic Oscillator
- INO 82.35
- IVVD 11.35
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.